Clinic Roundup

• Biotron Ltd., of Sydney, Australia, said it expects to deliver preliminary data from a Phase Ib/IIa study of lead HIV drug, BIT225, in the March quarter of 2013. BIT225 is designed to specifically target HIV in reservoir cells to stop the ongoing cycle of infection in the body.